Pharmacodynamic equivalence of two orlistat capsule formulations in healthy volunteers under fed conditions

International Journal of Clinical Pharmacology and Therapeutics

Volumn 46, Issue 6, 2008, Pages 319-326

  Di Marco, M ^a   Marier, J F ^b   Ducharme, M P ^c   Morin, I ^a   Engel, C ^a   Gulbranson, S ^b   Thudi, N R ^c   Murpani, D ^a   Rampal, A ^a   Monif, T ^a,d,e   Koundinya, T S ^a   Deo, K ^a  

^a MDS Inc   (Canada)

^b Pharsight Co   (Canada)

^c Cetero Research   (United States)

^d Ranbaxy Pharmaceuticals Canada Inc   (Canada)

^e RANBAXY LABORATORIES LTD   (India)

Author keywords

Orlistat capsules; Pharmacodynamics; Therapeutic equivalence

Indexed keywords

FECES LIPID; GENERIC DRUG; TETRAHYDROLIPSTATIN;

ADULT; ARTICLE; BIOEQUIVALENCE; CALORIC INTAKE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG CAPSULE; DRUG FORMULATION; FAT INTAKE; FECES ANALYSIS; FEMALE; HUMAN; HUMAN EXPERIMENT; LIPID ANALYSIS; LOOSE FECES; MALE; NORMAL HUMAN; PHARMACODYNAMICS; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; UNSPECIFIED SIDE EFFECT;

EID: 45949090160     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/cpp46319     Document Type: Article

References (14)

1. Chow SC, Liu JP. Design and analysis of bioavailabiliry and bioequivalence studies. New York, USA: Marcel Dekker Inc; 1992. p. 11-22.
2. Curran MP, Scott LJ. Orlistat: a review of its use in the management of patients with obesity. Drugs. 2004; 24: 2845-2864.
3. Guidance for Industry. Dissolution Testing of Immediate, Release Solid Oral Dosage Forms, US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), August 1997. http://www.fda.gov/cder/gaidance/1713bp1.pdf
4. Guidance for Industry. Statistical Approaches to Establishing Bioequivalence, US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), January 2001. http://www.fda.gov/cder/guidance/3616fnl.pdf.
5. Guidance for Industry. Food-Effect Bioavailability and Fed Bioequivalence Studies. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). December 2002. http://www.fda.gov/cder/guidance/5194fnl.pdf.
6. Lawrence VJ, Kopelman PG. Medical consequences of obesity. Clin Dermatol. 2004; 22: 296-302.
7. Lucas KH, Kaplan-Machlis B. Orlistat - a novel weight loss therapy. Ann Pharmacother. 2001; 35: 314-328.
8. Moore JW, Flanner HH. Mathematical comparison of dissolution profiles. Pharmaceutical Technology. 1996; 20: 64-74.
9. Rani S, Pargal A. Bioequivalence: an overview of statistical concepts. Indian J Pharmacol. 2004; 36: 209-216.
10. Scheen AJ, Lefebvre PJ. Antiobesity pharmacotherapy in the management of Type 2 diabetes. Diabetes Metab Res Rev. 2000; 16: 114-124.
11. Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm. 1987; 15: 657-680.
12. Zhi J, Melia AT, Eggers H et al. Review of limited systemic absorption of orlistat, a lipase inhibitor, in healthy human volunteers. J Clin Pharmacol. 1995; 35: 1103-1108.
13. Zhi J, Melia AT, Guerciolini R et al. Retrospective population-based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunteers. Clin Pharmacol Ther. 1994; 56: 82-85.
14. Zhi J, Melia AT, Funk C et al. Metabol ic profiles of minimally absorbed orlistat in obese/overweight volunteers. J Clin Pharmacol. 1996; 36: 1006-1011.